Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
K. Sakamoto & Y. Nakamura. (1994) Stereoselective disposition and metabolism of pinacidil in rat. Xenobiotica 24:4, pages 329-338.
Read now
Read now
K. Sakamoto & Y. Nakamura. (1993) Urinary metabolites of pinacidil. II. Species difference in the metabolism of pinacidil. Xenobiotica 23:6, pages 649-656.
Read now
Read now
K. Sakamoto & Y. Nakamura. (1993) Urinary metabolites of pinacidil: I. isolation and identification of the metabolites in rat urine. Xenobiotica 23:4, pages 391-400.
Read now
Read now
E. Eilertsen, J. W. Wart, M. P. Magnussen, H. Sørensen & E. Arrigoni-Martelli. (1982) Pharmacokinetics and distribution of the new antihypertensive agent pinacidil in rat, dog and man. Xenobiotica 12:3, pages 177-185.
Read now
Read now
Articles from other publishers (25)
Mark A. Simmons. 2009. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
7
.
E. Bellissant, NP Chau, C. Thuillez & JF Giudicelli. (2009) Pharmacokinetic‐pharmacodynamic modeling between pinacidil or pinacidil‐N‐oxide plasma levels and systemic and regional hemodynamic effects in healthy volunteers. Fundamental & Clinical Pharmacology 8:5, pages 437-445.
Crossref
Crossref
John M. Evans & Stephen G. Taylor. 1994.
411
446
.
P. Girard, J. L. Saumet, F. Dubois & J. P. Boissel. (1993) Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers. European Journal of Clinical Pharmacology 44:2, pages 177-182.
Crossref
Crossref
Karl‐Erik Andersson. (2009) Clinical Pharmacology of Potassium Channel Openers. Pharmacology & Toxicology 70:4, pages 244-254.
Crossref
Crossref
C Thuillez, E Pussard, E Bellissant, C Richer, R Kechrid & JF Giudicelli. (2012) Arterial vasodilating profile and biological effects of pinacidil in healthy volunteers.. British Journal of Clinical Pharmacology 31:1, pages 33-39.
Crossref
Crossref
Jens Erik Nielsen-Kudsk, Claus Brøckner Nielsen, Søren Mellemkjaer & Charlotte Siggaard. (1990) Lack of Effect of Pinacidil on Theophylline Pharmacokinetics and Metabolism in Man. Pharmacology & Toxicology 67:2, pages 156-158.
Crossref
Crossref
A. H. Weston. 1990. Pharmacology of Antihypertensive Therapeutics. Pharmacology of Antihypertensive Therapeutics
643
676
.
J. Elks & C. R. Ganellin. 1990. Dictionary of Drugs. Dictionary of Drugs
928
1053
.
R. Ayesh, M. Al-Waiz, A. McBurney, SC Mitchell, J.R. Idle, JW Ward & RL Smith. (1989) Variable metabolism of pinacidil: lack of correlation with the debrisoquine and trimethylamine C- and N-oxidative polymorphisms.. British Journal of Clinical Pharmacology 27:4, pages 423-428.
Crossref
Crossref
A. H. Weston. (1989) Smooth muscle K+ channel openers; their pharmacology and clinical potential. Pfl�gers Archiv European Journal of Physiology 414:S1, pages S99-S105.
Crossref
Crossref
Michael R. Goldberg, Frank W. Rockhold, W. Leigh Thompson & Karl A. DeSante. (2013) Clinical Pharmacokinetics of Pinacidil, A Potassium Channel Opener, in Hypertension. The Journal of Clinical Pharmacology 29:1, pages 33-40.
Crossref
Crossref
A.F. Delong, S.W. Oldham, K.A. Desante, G. Nell & D.P. Henry. (1988) Disposition of [14c]Pinacidil in Humans. Journal of Pharmaceutical Sciences 77:2, pages 153-156.
Crossref
Crossref
A. McBurney, J. A. Henry & J. W. Ward. (1988) Accumulation of pinacidil N-oxide during chronic treatment with pinacidil. European Journal of Clinical Pharmacology 35:1, pages 93-95.
Crossref
Crossref
Alan McBurney, Peter R. Farrow & John W. Ward. (1987) Effects of Formulation on the Pharmacokinetics of Orally Administered Pinacidil in Humans. Journal of Pharmaceutical Sciences 76:12, pages 940-941.
Crossref
Crossref
Marlene L. Cohen. (2008) Pinacidil monohydrate—a novel vasodilator: Review of preclinical pharmacology and mechanism of action. Drug Development Research 9:4, pages 249-258.
Crossref
Crossref
Marlene L. Cohen & Walter E. Colbert. (2008) Comparison of the effects of pinacidil and its metabolite, pinacidil‐N‐oxide, in isolated smooth and cardiac muscle. Drug Development Research 7:2, pages 111-124.
Crossref
Crossref
Marta Hamilton, Khadiga Z. Farid & David P. Henry. (1986) Liquid chromatographic determination of pinacidil, a new antihypertensive drug, and its major metabolite, pinacidil N-oxide, in plasma. Journal of Chromatography B: Biomedical Sciences and Applications 375, pages 359-367.
Crossref
Crossref
L. R. Krusell, C. K. Christensen & O. Lederballe Pedersen. (1986) Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy. European Journal of Clinical Pharmacology 30:6, pages 641-647.
Crossref
Crossref
Mark S Laher & Michael P Hickey. (2016) Pharmacokinetics and Bioavailability of Pinacidil Capsules in Human Volunteers. Journal of International Medical Research 13:3, pages 159-162.
Crossref
Crossref
Edoardo Arrigoni‐Martelli & Jim Finucane. (2007) Pinacidil. Cardiovascular Drug Reviews 3:1, pages 133-151.
Crossref
Crossref
A McBurney, PR Farrow, S Ainsworth & JW Ward. (1985) Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following i.v. and oral administration in healthy volunteers.. British Journal of Clinical Pharmacology 19:1, pages 91-94.
Crossref
Crossref
E. G. Breen, D. Mulhall & J. A. B. Keogh. (1985) Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: A new vasodilator. European Journal of Clinical Pharmacology 28:4, pages 381-386.
Crossref
Crossref
E. G. Breen, D. Mulhall & J. A. B. Keogh. (1985) Long-term effects of pinacidil in hypertensive dialysis patients. European Journal of Clinical Pharmacology 28:4, pages 375-380.
Crossref
Crossref
J. W. Ward, A. McBurney, P. R. Farrow & P. Sharp. (1984) Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator. European Journal of Clinical Pharmacology 26:5, pages 603-608.
Crossref
Crossref